Targets › TRAIL-R2
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Jan 2029.
Open in Phaseline: the race on TRAIL-R2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Baylor College of Medicine | HTR2 T Cells TRAIL-R2 and HER2 bi-specific chimeric antigen receptor (CAR) T cells | TRAIL-R2, ERBB2 | Phase 1 | Breast Cancer | Jan 2029 |
Breast Cancer (1)
other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.